Compare NEXA & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEXA | RAPP |
|---|---|---|
| Founded | 1956 | 2022 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2017 | 2024 |
| Metric | NEXA | RAPP |
|---|---|---|
| Price | $15.11 | $37.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $10.40 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 1.2M | 288.7K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.69 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.62 | $10.57 |
| 52 Week High | $16.89 | $42.27 |
| Indicator | NEXA | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 52.44 |
| Support Level | $13.68 | $25.48 |
| Resistance Level | $16.82 | $41.18 |
| Average True Range (ATR) | 0.89 | 2.02 |
| MACD | 0.03 | -0.23 |
| Stochastic Oscillator | 55.90 | 53.72 |
Nexa Resources SA operate large-scale, mechanized underground and open pit mines, as well as smelters. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.